Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Место прогестагенных оральных контрацептивов в гинекологической практике

https://doi.org/10.33667/2078-5631-2019-1-1(376)-19-26

Полный текст:

Аннотация

В обзоре литературы представлены данные о возможных рисках применения комбинированной гормональной контрацепции и возможностях назначения чисто прогестагенной контрацепции как альтернативы применения комбинированных средств. Прогестагенные контрацептивы включают группу средств с разными способами введения, дозами и характеристиками прогестинов, имеющих ряд отличий по соотношению пользы и риска, доступности, обратимости и другим свойствам контрацепции. Особое внимание уделено чисто прогестагенным таблеткам, содержащим дезогестрел, как средству, эквивалентному по эффективности комбинированным контрацептивам, но более безопасному. Вопросы безопасности рассмотрены в контексте применения кормящими грудью женщинами, а также с позиций риска артериального и венозного тромбоза. Освещены вопросы неконтрацептивных положительных эффектов чисто прогестагенных контрацептивов.

Об авторе

И. В. Кузнецова
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова» Минздрава России
Россия


Список литературы

1. Sitruk-Ware R, Nath A, Mishell DR Jr. Contraception technology: past, present and future. Contraception. 2013; 87(3): 319-330.

2. Shulman LP. The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives. Am J Obstet Gynecol. 2011; 14: S 9-S 13.

3. Lidegaard Ø, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009; 14: b2890.

4. Birgisson NE, Zhao Q, Secura GM, Madden T, Peipert JF. Preventing Unintended Pregnancy: The Contraceptive CHOICE Project in Review. Journal of women’s health. 2015; 24 (5): 349-353.

5. World Health Organization, Department of Reproductive Health. Medical eligibility criteria wheel for contraceptive use; 2015.

6. Burke AE. The state of hormonal contraception today: benefits and risks of hormonal contraceptives: progestin-only contraceptives. Am J Obstet Gynecol. 2011; 14: S14-S 17.

7. Guzeloglu-Kayisli O, Basar M, Shapiro JP, et al. Long-acting progestin-only contraceptives enhance human endometrial stromal cell expressed neuronal pentraxin-1 and reactive oxygen species to promote endothelial cell apoptosis. J Clin EndocrinolMetab. 2014; 99 (10): E 1957-1966.

8. Glisic M, Shahzad S, Tsoli S, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2018; 25 (10): 1042-1052.

9. Jacobstein R, Polis CB. Progestin-only contraception: injectables and implants. Best Pract Res Clin Obstet Gynaecol. 2014; 28 (6): 795-806.

10. Hapgood JP, Kaushic Ch, Hel Z. Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms. Endocr Rev. 2018; 39 (1): 36-78.

11. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgesfrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30: 2297-2300.

12. Hidalgo MM, Hidalgo-Regina C, Bahamondes MV, Monteiro I, Petta CA, Bahamondes L. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception. 2009; 80 (1): 84-89.

13. Caruso S, Cianci S, Vitale SG, Fava V, Cutello S, Cianci A. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy. Eur J Contracept Reprod Health Care. 2018; 23 (1): 24-31.

14. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011; 76 (7): 636-652.

15. Pena MÂ, Sanz E, Francisco S, et al. Randomized, Crossover and Single-Dose Bioquivalence Study of Two Oral Desogestrel Formulations (Film-Coated Tablets of 75 fjg) in Healthy Female Volunteers. Sci Pharm. 2012; 80 (2): 419-431.

16. Regidor P-A. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018; 9 (77): 34628-34648.

17. Lockwood CJ. Mechanisms of normal and abnormal endometrial bleeding. Menopause. 2011; 18 (4): 408-411.

18. World Health Organization. Progestogen-only contraceptive use during lactation and its effects on the neonate. www.who.int/ reproductivehealth/publications/family_ planning/WHO_RHR_09_13/en/. Retrived December 6th 2016.

19. Lopez LM, Grey TW, Stuebe AM, Chen M, Truitt ST, Gallo MF. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Cochrane Database Syst Rev. 2015; 3: CD 003988.

20. Peragallo Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, et al. Risk of acute thromboembolic events with oral contraceptive use: A systematic review and meta-analysis. Obstet Gynecol. 2013; 122: 380-389.

21. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012; 14: e4944.

22. Dhont M, Verhaeghe V. Hormonal anticonception anno 2013: a clinician’s view. FVV in ObGyn 2013; 5 (2): 149-159.

23. Quist-Paulsen P, Nœss IA, Cannegieter SC, Romundstad PR, Christiansen SC, Rosendaal FR, Hammerstr0m J. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica. 2010; 95 (1): 119-125.

24. Wang C, Li Y, Li H, et al. Increased risk of stroke in oral contraceptive users carried replicated genetic variants: a population-based case-control study in China. Hum Genet 2012; 131 (8): 1337-1344.

25. Havrilesky LJ, Gierisch JM, Moorman PG, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep) 2013; 212: 1-514.

26. Lidegaard Ø, L0kkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012; 14: 2257-2266.

27. MacGregor EA. Contraception and headache. Headache 2013; 14: 247-276.

28. Chakhtoura Z, Canonico M, Gompel A, Thalabard JC, Scarabin PY, Plu-Bureau G. Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke. 2009; 14: 1059-1062.

29. Albright M, Rani S, Gavagan T. HelpDesk answers: do hormonal contraceptives lead to weight gain? J Fam Pract. 2015; 64 (6): 371-372.

30. Lopez LM, Ramesh S, Chen M, Edelman A, Otterness C, Trussell J, Helmerhorst FM. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2016; (8): CD 008815.

31. Shufelt CL, Bairey Merz CN. Contraceptive Hormone Use and Cardiovascular Disease. J Am Coll Cardiol. 2009; 53 (3): 221-231.

32. Spector JT, Kahn SR, Jones MR, Jayakumar M, DalalD, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med. 2010; 14: 612-624.

33. Nappi RE, Berga SL. Migraine and reproductive life. Handb Clin Neurol. 2010; 14:303-322.

34. Champaloux SW, Tepper NK, Monsour M, Curtis KM, Whiteman MK, Marchbanks PA, Jamieson DJ. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017; 216: 489.e1-489.e7.

35. Sacco S, Ricci S, Carolei A. Migraine and vascular diseases: potential implications for management. Cephalalgia. 2012; 32: 785-795.

36. Sacco S, Kurth T. Migraine and the risk of stroke and cardiovascular disease. Curr Cardiol Rep. 2014; 16: 524.

37. Sacco S, Merki-Feld GS, Ægidius KL, et al, European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). HCs and risk of ischemic stroke in women with migraine: a consensus statement from the European headache federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain 2017; 18: 108.

38. Morotti M, Remorgida V, Venturini PL, Ferrero S. Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. Eur J Obstet Gynecol Reprod Biol. 2014; 179:63-68.

39. Merki-Feld GS, Imthurn B, Dubey R, Sdndor PS, Gantenbein AR. Improvement of migraine with change from combined hormonalcontraceptives to progestin-only contraception with desogestrel: how strong is the effect of taking women off combined contraceptives? J Obstet Gynaecol. 2017; 37: 338-341.

40. Nappi RE, Sances G, Allais G, Terreno E, Benedetto C, Vaccaro V, Polatti F, Facchinetti F. Effects of an estrogen-free, desogestrel containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. Contraception. 2011; 83: 223-228.

41. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018; 38: 1-211.

42. Vetvik KG, Macgregor EA, Lundqvist C, Russell MB. Prevalence of menstrual migraine: a population-based study. Cephalalgia. 2014; 15 (4): 280-288.

43. MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2014; 3: 354-361.

44. Sacco S, Ricci S, Deagn D, Carolei A. Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain. 2012; 13: 177-189.

45. Machado RB, Pereira AP, Coelho GP, Neri L, Martins L, Luminoso D. Epidemiological and clinical aspects of migraine in users of combined oral contraceptives. Contraception. 2010; 15 (3): 202-208.

46. Kvisvik EV, Stovner LJ, Helde G, Bovim G, Linde M. Headache and migraine during pregnancy and puerperium: the MIGRA-study. J Headache Pain. 2011; 15 (4): 443-451.

47. Greco R, Tassorelli C, Mangione AS, Smeraldi A, Allena M, Sandrini G, Nappi G, Nappi RE. Effect of sex and estrogens on neuronal activation in an animal model of migraine. Headache. 2013; 14: 288-296.

48. Табеева Г. Р., Громова С. А. Эстрогены и мигрень. Неврологический журнал. 2009; 5: 45-53.

49. Durham PL, Vause CV, DerosierF, McDonald S, Cady R, Martin V. Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea. Headache. 2010; 15 (5): 844-851.

50. Bolay H, Berman NE, Akcali D. Sex-related differences in animal models of migraine headache. Headache. 2011; 14: 891-904.

51. Jayaraman A, Pike CJ. Progesterone attenuates oestrogen neuroprotection via down-regulation of oestrogen receptor expression in cultured neurones. J Neuroendocrinol. 2009; 14: 77-81.

52. Warhurst S, Rofe CJ, Brew BJ, Bateson D, McGeechan K, Merki-Feld GS, Garrick R, Tomlinson SE. Effectiveness of the progestin-only pill for migraine treatment in women: a systematic review and meta-analysis. Cephalalgia. 2018; 38: 754-764.

53. MacGregor EA. Prevention and treatment of menstrual migraine. Drugs. 2010. 70: 1799-1818.

54. Vetvik KG, MacGregor EA, Lundqvist C, Russell MB. Contraceptive-induced amenorrhoea leads to reduced migraine frequency in women with menstrual migraine without aura. J Headache Pain. 2014; 15 (1): 30.

55. Sacco S, Merki-Feld GS, Ægidius KL et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain. 2018; 19: 76.

56. Krikun G, Booth CJ, Buchwalder L, et al. Long-term progestin-only contraception in humans versus animal models. Annals of the New York Academy of Sciences. 2011; 1221: 119-123.

57. Evans SF, Brooks TA, Esterman AJ, Hull ML, Rolan PE. The comorbidities of dysmenorrhea: a clinical survey comparing symptom profile in women with and without endometriosis. J Pain Res. 2018; 11: 3181-3194.


Для цитирования:


Кузнецова И.В. Место прогестагенных оральных контрацептивов в гинекологической практике. Медицинский алфавит. 2019;1(1):19-26. https://doi.org/10.33667/2078-5631-2019-1-1(376)-19-26

For citation:


Kuznetsova I.V. Place of progestogenic oral contraceptives in gynecological practice. Medical alphabet. 2019;1(1):19-26. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-1(376)-19-26

Просмотров: 30


ISSN 2078-5631 (Print)